MAIA Completes Enrollment
MAIA Biotechnology completes international enrollment in Part C of Phase 2 THIO-101 expansion trial in third-line non-small cell lung cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.